Lesa L Aylward

List of Publications by Year
in descending order

134 papers	5,220 citations	66343 42 h-index	106344 65 g-index
136 all docs	136 docs citations	136 times ranked	4649 citing authors

#	Article	IF	Citations
1	Biomonitoring equivalents: A screening approach for interpreting biomonitoring results from a public health risk perspective. Regulatory Toxicology and Pharmacology, 2007, 47, 96-109.	2.7	219
2	Age as a determinant of phosphate flame retardant exposure of the Australian population and identification of novel urinary PFR metabolites. Environment International, 2015, 74, 1-8.	10.0	211
3	Human biomonitoring assessment values: Approaches and data requirements. International Journal of Hygiene and Environmental Health, 2011, 214, 348-360.	4.3	156
4	Guidelines for the derivation of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology, 2008, 51, S4-S15.	2.7	147
5	Sources of Variability in Biomarker Concentrations. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2014, 17, 45-61.	6.5	133
6	Elevated levels of PFOS and PFHxS in firefighters exposed to aqueous film forming foam (AFFF). Environment International, 2015, 82, 28-34.	10.0	130
7	Concentration-dependent TCDD elimination kinetics in humans: toxicokinetic modeling for moderately to highly exposed adults from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort. Journal of Exposure Science and Environmental Epidemiology, 2005, 15, 51-65.	3.9	127
8	Evaluation of Biomonitoring Data from the CDC National Exposure Report in a Risk Assessment Context: Perspectives across Chemicals. Environmental Health Perspectives, 2013, 121, 287-294.	6.0	126
9	Dioxin risks in perspective: past, present, and future. Regulatory Toxicology and Pharmacology, 2003, 37, 202-217.	2.7	111
10	Guidelines for the communication of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology, 2008, 51, S16-S26.	2.7	99
11	Temporal trends in human TCDD body burden: Decreases over three decades and implications for exposure levels. Journal of Exposure Science and Environmental Epidemiology, 2002, 12, 319-328.	3.9	98
12	Inter- and intra-individual variation in urinary biomarker concentrations over a 6-day sampling period. Part 2: Personal care product ingredients. Toxicology Letters, 2014, 231, 261-269.	0.8	96
13	Variation in Urinary Flow Rates According to Demographic Characteristics and Body Mass Index in NHANES: Potential Confounding of Associations between Health Outcomes and Urinary Biomarker Concentrations. Environmental Health Perspectives, 2015, 123, 293-300.	6.0	89
14	Advancing Exposure Characterization for Chemical Evaluation and Risk Assessment. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2010, 13, 299-313.	6.5	87
15	Human Response to Dioxin: Aryl Hydrocarbon Receptor (AhR) Molecular Structure, Function, and Dose-Response Data for Enzyme Induction Indicate an Impaired Human AhR. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2006, 9, 147-171.	6.5	85
16	Biomonitoring Equivalents (BE) dossier for cadmium (Cd) (CAS No. 7440-43-9). Regulatory Toxicology and Pharmacology, 2008, 51, S49-S56.	2.7	82
17	Using Biomonitoring Equivalents to interpret human biomonitoring data in a public health risk context. Journal of Applied Toxicology, 2009, 29, 275-288.	2.8	81
18	Interpreting variability in population biomonitoring data: Role of elimination kinetics. Journal of Exposure Science and Environmental Epidemiology, 2012, 22, 398-408.	3.9	78

#	Article	IF	Citations
19	Relationships of Chemical Concentrations in Maternal and Cord Blood: A Review of Available Data. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2014, 17, 175-203.	6.5	77
20	Pooled biological specimens for human biomonitoring of environmental chemicals: Opportunities and limitations. Journal of Exposure Science and Environmental Epidemiology, 2014, 24, 225-232.	3.9	73
21	Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy. Journal of Exposure Science and Environmental Epidemiology, 2009, 19, 634-642.	3.9	72
22	Biomonitoring Equivalents for inorganic arsenic. Regulatory Toxicology and Pharmacology, 2010, 58, 1-9.	2.7	71
23	Mode of action and doseâ€“response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study. Critical Reviews in Toxicology, 2014, 44, 83-119.	3.9	69
24	Biomonitoring Equivalents for bisphenol A (BPA). Regulatory Toxicology and Pharmacology, 2010, 58, 18-24.	2.7	65
25	Biomonitoring Equivalents for selenium. Regulatory Toxicology and Pharmacology, 2014, 70, 333-339.	2.7	65
26	Variation in urinary spot sample, 24â€‰h samples, and longer-term average urinary concentrations of short-lived environmental chemicals: implications for exposure assessment and reverse dosimetry. Journal of Exposure Science and Environmental Epidemiology, 2017, 27, 582-590.	3.9	65
27	Exposure and toxicity characterization of chemical emissions and chemicals in products: global recommendations and implementation in USEtox. International Journal of Life Cycle Assessment, 2021, 26, 899-915.	4.7	58
28	Derivation of Biomonitoring Equivalents for di-n-butyl phthalate (DBP), benzylbutyl phthalate (BzBP), and diethyl phthalate (DEP). Regulatory Toxicology and Pharmacology, 2009, 55, 259-267.	2.7	56
29	Mortality Rates Among Trichlorophenol Workers With Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. American Journal of Epidemiology, 2009, 170, 501-506.	3.4	53
30	Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters. International Journal of Hygiene and Environmental Health, 2018, 221, 1068-1075.	4.3	52
31	Relative Susceptibility of Animals and Humans to the Cancer Hazard Posed by 2,3,7,8-Tetrachlorodibenzo-p- dioxin Using Internal Measures of Dose. Environmental Science & Technology, 1996, 30, 3534-3543.	10.0	51
32	Biomonitoring Equivalents (BE) dossier for 2,4-dichlorophenoxyacetic acid (2,4-D) (CAS No. 94-75-7). Regulatory Toxicology and Pharmacology, 2008, 51, S37-S48.	2.7	51
33	Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chemico-Biological Interactions, 2012, 200, 45-64.	4.0	51
34	Per- and polyfluoroalkyl substances (PFAS) in Australia: Current levels and estimated population reference values for selected compounds. International Journal of Hygiene and Environmental Health, 2019, 222, 387-394.	4.3	51
35	Human biomonitoring as a pragmatic tool to support health risk management of chemicals â€“ Examples under the EU REACH programme. Regulatory Toxicology and Pharmacology, 2011, 59, 125-132.	2.7	49
36	A pilot study of oral bioavailability of dioxins and furans from contaminated soils: Impact of differential hepatic enzyme activity and species differences. Chemosphere, 2008, 70, 1774-1786.	8.2	47

#	Article	IF	Citations
37	Biomonitoring Equivalents for DDT/DDE. Regulatory Toxicology and Pharmacology, 2011, 60, 172-180.	2.7	47
38	Evaluation of urinary speciated arsenic in NHANES: Issues in interpretation in the context of potential inorganic arsenic exposure. Regulatory Toxicology and Pharmacology, 2014, 69, 49-54.	2.7	47
39	Evaluation of human biomonitoring data in a health risk based context: An updated analysis of population level data from the Canadian Health Measures Survey. International Journal of Hygiene and Environmental Health, 2020, 223, 267-280.	4.3	47
40	Age-Related Trends in Urinary Excretion of Bisphenol A in Australian Children and Adults: Evidence from a Pooled Sample Study Using Samples of Convenience. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2013, 76, 1039-1055.	2.3	44
41	Advancements in Life Cycle Human Exposure and Toxicity Characterization. Environmental Health Perspectives, 2018, 126, 125001.	6.0	44
42	Screening of population level biomonitoring data from the Canadian Health Measures Survey in a risk-based context. Toxicology Letters, 2014, 231, 126-134.	0.8	43
43	Inter- and intra-individual variation in urinary biomarker concentrations over a 6-day sampling period. Part 1: Metals. Toxicology Letters, 2014, 231, 249-260.	0.8	42
44	Biomonitoring Equivalents for interpretation of urinary fluoride. Regulatory Toxicology and Pharmacology, 2015, 72, 158-167.	2.7	42
45	Biomonitoring Equivalents for molybdenum. Regulatory Toxicology and Pharmacology, 2016, 77, 223-229.	2.7	40
46	Derivation of Biomonitoring Equivalents for di(2-ethylhexyl)phthalate (CAS No. 117-81-7). Regulatory Toxicology and Pharmacology, 2009, 55, 249-258.	2.7	38
47	Age-specific Reference Ranges for Polychlorinated Biphenyls (PCB) Based on the NHANES 2001â€“2002 Survey. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2007, 70, 1873-1877.	2.3	37
48	Perspective on serum dioxin levels in the United States: an evaluation of the NHANES data. Journal of Exposure Science and Environmental Epidemiology, 2009, 19, 435-441.	3.9	37
49	Biomonitoring Equivalents for di-isononyl phthalate (DINP). Regulatory Toxicology and Pharmacology, 2011, 60, 181-188.	2.7	37
50	Interpreting human biomonitoring data in a public health risk context using Biomonitoring Equivalents. International Journal of Hygiene and Environmental Health, 2012, 215, 145-148.	4.3	37
51	Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chemico-Biological Interactions, 2013, 204, 13-27.	4.0	37
52	Phthalate esters in face masks and associated inhalation exposure risk. Journal of Hazardous Materials, 2022, 423, 127001.	12.4	37
53	Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1). Regulatory Toxicology and Pharmacology, 2008, 51, S57-S67.	2.7	36
54	Biomonitoring Data for 2,4-Dichlorophenoxyacetic Acid in the United States and Canada: Interpretation in a Public Health Risk Assessment Context Using Biomonitoring Equivalents. Environmental Health Perspectives, 2010, 118, 177-181.	6.0	36

#	Article	IF	Citations
55	Biomonitoring Equivalents for triclosan. Regulatory Toxicology and Pharmacology, 2010, 58, 10-17.	2.7	35
56	Biomonitoring Equivalents for deltamethrin. Regulatory Toxicology and Pharmacology, 2011, 60, 189-199.	2.7	35
57	An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD). Regulatory Toxicology and Pharmacology, 2004, 40, 9-17.	2.7	34
58	Public health interpretation of trihalomethane blood levels in the United States: NHANES 1999â€“2004. Journal of Exposure Science and Environmental Epidemiology, 2010, 20, 255-262.	3.9	34
59	Urinary DEHP metabolites and fasting time in NHANES. Journal of Exposure Science and Environmental Epidemiology, 2011, 21, 615-624.	3.9	34
60	Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere, 2012, 89, 487-493.	8.2	34
61	Exposure Reconstruction for the TCDD-Exposed NIOSH Cohort Using a Concentration- and Age-Dependent Model of Elimination. Risk Analysis, 2005, 25, 945-956.	2.7	33
62	Serum measures of hexabromocyclododecane (HBCDD) and polybrominated diphenyl ethers (PBDEs) in reproductive-aged women in the United Kingdom. Environmental Research, 2019, 177, 108631.	7.5	33
63	Mortality Rates Among Workers Exposed to Dioxins in the Manufacture of Pentachlorophenol. Journal of Occupational and Environmental Medicine, 2009, 51, 1212-1219.	1.7	30
64	Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs) â€“ Application of steady-state PBPK model solutions. Regulatory Toxicology and Pharmacology, 2010, 58, 33-44.	2.7	30
65	Biomonitoring-based risk assessment for hexabromocyclododecane (HBCD). International Journal of Hygiene and Environmental Health, 2011, 214, 179-187.	4.3	30
66	Biomonitoring Equivalents for benzene. Regulatory Toxicology and Pharmacology, 2012, 62, 62-73.	2.7	30
67	Urinary excretion and daily intake rates of diethyl phthalate in the general Canadian population. Science of the Total Environment, 2014, 500-501, 191-198.	8.0	29
68	Screening-level Biomonitoring Equivalents for tiered interpretation of urinary 3-phenoxybenzoic acid (3-PBA) in a risk assessment context. Regulatory Toxicology and Pharmacology, 2018, 92, 29-38.	2.7	29
69	Mortality in Workers Exposed to 2,3,7,8-Tetrachlorodibenzo-p-dioxin at a Trichlorophenol Plant in New Zealand. Journal of Occupational and Environmental Medicine, 2009, 51, 1049-1056.	1.7	27
70	Biomonitoring equivalents for hexachlorobenzene. Regulatory Toxicology and Pharmacology, 2010, 58, 25-32.	2.7	27
71	A mechanism-based cancer risk assessment for 1,4-dichlorobenzene. Regulatory Toxicology and Pharmacology, 2007, 49, 138-148.	2.7	26
72	Biomonitoring Equivalents (BE) dossier for toluene (CAS No. 108-88-3). Regulatory Toxicology and Pharmacology, 2008, 51, S27-S36.	2.7	26

#	Article	IF	Citations
73	Short term variability in urinary bisphenol A in Australian children. Environment International, 2014, 68, 139-143.	10.0	26
74	Derivation of Biomonitoring Equivalents for cyfluthrin. Regulatory Toxicology and Pharmacology, 2009, 55, 268-275.	2.7	25
75	Population variation in biomonitoring data for persistent organic pollutants (POPs): An examination of multiple population-based datasets for application to Australian pooled biomonitoring data. Environment International, 2014, 68, 127-138.	10.0	24
76	Pesticide metabolite concentrations in Queensland pre-schoolers â€“ Exposure trends related to age and sex using urinary biomarkers. Environmental Research, 2019, 176, 108532.	7.5	24
77	TCDD Exposure-Response Analysis and Risk Assessment. Risk Analysis, 2006, 26, 1059-1071.	2.7	23
78	Estimates of Cancer Potency of 2,3,7,8-Tetrachlorodibenzo(p)dioxin Using Linear and Nonlinear Dose-Response Modeling and Toxicokinetics. Toxicological Sciences, 2009, 112, 490-506.	3.1	23
79	Persistent organic pollutants in matched breast milk and infant faeces samples. Chemosphere, 2015, 118, 309-314.	8.2	22
80	Is Age an Independent Risk Factor for Chemically Induced Acute Myelogenous Leukemia in Children?. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2007, 10, 379-400.	6.5	21
81	Derivation of Biomonitoring Equivalent (BE) Values for 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds: A Screening Tool for Interpretation of Biomonitoring Data in a Risk Assessment Context. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2008, 71, 1499-1508.	2.3	20
82	Biomonitoring Equivalents for 2,2â€²,4,4â€²,5-pentabromodiphenylether (PBDE-99). Regulatory Toxicology and Pharmacology, 2011, 60, 165-171.	2.7	20
83	2,4-D Exposure and risk assessment: Comparison of external dose and biomonitoring based approaches. Regulatory Toxicology and Pharmacology, 2012, 64, 481-489.	2.7	20
84	Elimination Rates of Dioxin Congeners in Former Chlorophenol Workers from Midland, Michigan. Environmental Health Perspectives, 2013, 121, 39-45.	6.0	20
85	Consideration of dosimetry in evaluation of <scp>ToxCast</scp>â„¢ data. Journal of Applied Toxicology, 2011, 31, 741-751.	2.8	19
86	Evaluation of NHANES biomonitoring data for volatile organic chemicals in blood: Application of chemical-specific screening criteria. Journal of Exposure Science and Environmental Epidemiology, 2012, 22, 24-34.	3.9	19
87	Biomonitoring Equivalents (BE) dossier for trihalomethanes. Regulatory Toxicology and Pharmacology, 2008, 51, S68-S77.	2.7	18
88	Temporal trends in serum polybrominated diphenyl ether concentrations in the Australian population, 2002â€“2013. Environment International, 2018, 121, 357-364.	10.0	18
89	Issues in Risk Assessment for Developmental Effects of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin and Related Compounds. Toxicological Sciences, 2005, 87, 3-10.	3.1	17
90	Interpreting biomonitoring data for 2,4-dichlorophenoxyacetic acid: Update to Biomonitoring Equivalents and population biomonitoring data. Regulatory Toxicology and Pharmacology, 2015, 73, 765-769.	2.7	17

#	Article	IF	Citations
91	Sex ratio of the offspring of Sprague–Dawley rats exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in utero and lactationally in a three-generation study. Toxicology and Applied Pharmacology, 2006, 216, 29-33.	2.8	16
92	Toxicokinetics Of 2,3,7,8-TCDF and 2,3,4,7,8-PeCDF in Mink (Mustela vison) at Ecologically Relevant Exposures. Toxicological Sciences, 2008, 105, 33-43.	3.1	16
93	Integration of biomonitoring data into risk assessment. Current Opinion in Toxicology, 2018, 9, 14-20.	5.0	15
94	"Intrinsic" elimination rate and dietary intake estimates for selected indicator PCBs: Toxicokinetic modeling using serial sampling data in US subjects, 2005–2010. Chemosphere, 2014, 110, 48-52.	8.2	14
95	Does dioxin exert toxic effects in humans at or near current background body levels?: an evidence-based conclusion. Human and Experimental Toxicology, 2006, 25, 99-105.	2.2	13
96	Introduction to the Biomonitoring Equivalents Pilot Project: Development of guidelines for the derivation and communication of Biomonitoring Equivalents. Regulatory Toxicology and Pharmacology, 2008, 51, S1-S2.	2.7	12
97	California biomonitoring data: Comparison to NHANES and interpretation in a risk assessment context. Regulatory Toxicology and Pharmacology, 2015, 73, 875-884.	2.7	12
98	Biomonitoring Equivalents for interpretation of urinary iodine. Regulatory Toxicology and Pharmacology, 2018, 94, 40-46.	2.7	12
99	Pesticide exposure in New Zealand school-aged children: Urinary concentrations of biomarkers and assessment of determinants. Environment International, 2022, 163, 107206.	10.0	12
100	A Margin-of-Exposure Approach to Assessment of Noncancer Risks of Dioxins Based on Human Exposure and Response Data. Environmental Health Perspectives, 2008, 116, 1344-1351.	6.0	11
101	Development of Screening Tools for the Interpretation of Chemical Biomonitoring Data. Journal of Toxicology, 2012, 2012, 1-10.	3.0	11
102	The relative susceptibility of animals and humans to the carcinogenic hazard posed by exposure to 2,3,7,8-TCDD: An analysis using standard and internal measures of dose. Chemosphere, 1997, 34, 1507-1522.	8.2	10
103	Correlates of serum dioxin to self-reported exposure factors. Environmental Research, 2010, 110, 131-136.	7.5	10
104	Tissue distribution of dioxin-like compounds: Potential impacts on systemic relative potency estimates. Toxicology Letters, 2013, 220, 294-302.	0.8	10
105	Exposure to selected preservatives in personal care products: case study comparison of exposure models and observational biomonitoring data. Journal of Exposure Science and Environmental Epidemiology, 2020, 30, 28-41.	3.9	10
106	Relative Cancer Potencies of Selected Dioxin-Like Compounds on a Body-Burden Basis: Comparison to Current Toxic Equivalency Factors (TEFs). Journal of Toxicology and Environmental Health - Part A: Current Issues, 2006, 69, 907-917.	2.3	9
107	Assessment of margin of exposure based on biomarkers in blood: An exploratory analysis. Regulatory Toxicology and Pharmacology, 2011, 61, 44-52.	2.7	9
108	Application of human biomonitoring (HBM) of chemical exposure in the characterisation of health risks under REACH. International Journal of Hygiene and Environmental Health, 2012, 215, 238-241.	4.3	9

#	Article	IF	Citations
109	Quantitative Propertyâ€“Property Relationship for Screening-Level Prediction of Intrinsic Clearance: A Tool for Exposure Modeling for High-Throughput Toxicity Screening Data. Applied in Vitro Toxicology, 2015, 1, 140-146.	1.1	9
110	Environmental chemicals in people: challenges in interpreting biomonitoring information. Journal of Environmental Health, 2008, 70, 61-4.	0.5	9
111	Association of endocrine active environmental compounds with body mass index and weight loss following bariatric surgery. Clinical Endocrinology, 2020, 93, 280-287.	2.4	8
112	TCDD exposure estimation for workers at a New Zealand 2,4,5-T manufacturing facility based on serum sampling data. Journal of Exposure Science and Environmental Epidemiology, 2010, 20, 417-426.	3.9	7
113	Application of pharmacokinetic modelling for 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure assessment. SAR and QSAR in Environmental Research, 2014, 25, 873-890.	2.2	7
114	Mortality risk among workers with exposure to dioxins. Occupational Medicine, 2016, 66, 706-712.	1.4	7
115	Monthly variation in faeces:blood concentration ratio of persistent organic pollutants over the first year of life: a case study of one infant. Environmental Research, 2016, 147, 259-268.	7.5	7
116	How Many Urine Samples Are Needed to Accurately Assess Exposure to Non-Persistent Chemicals? The Biomarker Reliability Assessment Tool (BRAT) for Scientists, Research Sponsors, and Risk Managers. International Journal of Environmental Research and Public Health, 2020, 17, 9102.	2.6	7
117	Estimates of Cancer Potency of 2,3,4,7,8-Pentachlorodibenzofuran Using Both Nonlinear and Linear Approaches. Toxicological Sciences, 2008, 106, 519-537.	3.1	6
118	Hepatic P450 Enzyme Activity, Tissue Morphology and Histology of Mink (Mustela vison) Exposed to Polychlorinated Dibenzofurans. Archives of Environmental Contamination and Toxicology, 2009, 57, 416-425.	4.1	6
119	Interpreting Estrogen Screening Assays in the Context of Potency and Human Exposure Relative to Natural Exposures to Phytoestrogens. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2014, 101, 114-124.	1.4	6
120	Biomarkers of Environmental Exposures in Blood. , 2019, , 376-385.		6
121	Comparison of lipid-normalised concentrations of persistent organic pollutants (POPs) between serum and adipose tissue. International Journal of Hygiene and Environmental Health, 2021, 236, 113801.	4.3	6
122	Biomonitoring Equivalents for interpretation of silver biomonitoring data in a risk assessment context. International Journal of Hygiene and Environmental Health, 2016, 219, 521-526.	4.3	5
123	Persistent organic pollutants in infants and toddlers: Relationship between concentrations in matched plasma and faecal samples. Environment International, 2017, 107, 82-88.	10.0	5
124	RAPID COMMUNICATION: BACKGROUND CONCENTRATIONS OF DIOXINS, FURANS, AND PCBs IN SPRAGUE-DAWLEY RATS AND JUVENILE SWINE. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2004, 67, 845-850.	2.3	4
125	Cohort study of workers at a New Zealand agrochemical plant to assess the effect of dioxin exposure on mortality. BMJ Open, 2018, 8, e019243.	1.9	4
126	Nondestructive Scat Sampling in Assessment of Mink (Mustela vison) Exposed to Polychlorinated Dibenzofurans (PCDFs). Archives of Environmental Contamination and Toxicology, 2008, 55, 529-537.	4.1	3

#	Article	IF	Citations
127	Biomonitoring of per- and polyfluoroalkyl substances (PFAS) exposure in firefighters: Study design and lessons learned from stakeholder and participant engagement. International Journal of Hygiene and Environmental Health, 2022, 242, 113966.	4.3	3
128	Comment on â€œRelative Susceptibility of Animals and Humans to the Cancer Hazard Posed by 2,3,7,8-Tetrachlorodibenzo-p-dioxin Using Internal Measures of Doseâ€• Environmental Science & Technology, 1998, 32, 549-550.	10.0	1
129	Response to Comment on â€œRelative Susceptibility of Animals and Humans to the Cancer Hazard Posed by 2,3,7,8-Tetrachlorodibenzo-p-dioxin Using Internal Measures of Doseâ€• Environmental Science & Technology, 1998, 32, 551-552.	10.0	1
130	Re: analysis of dioxin cancer threshold.. Environmental Health Perspectives, 2003, 111, A510.	6.0	0
131	Estimating Past Dioxin Exposure: Response to Steenland and Bartell. Risk Analysis, 2007, 27, 9-10.	2.7	0
132	Comment on â€œChronic Disease and Early Exposure to Air-Borne Mixtures. 2. Exposure Assessmentâ€• Environmental Science & Technology, 2008, 42, 2201-2201.	10.0	0
133	THREE AUTHORS REPLY. American Journal of Epidemiology, 2010, 171, 130-131.	3.4	0
134	Biomonitoring for POPs. , 2014, , 163-197.		0